• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjectsProfilesView

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    A phase II trial of second-line axitinib following prior antiangiogenic therapy in advanced hepatocellular carcinoma.

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Thumbnail
    Name:
    cncr.29227.pdf
    Size:
    257.3Kb
    Format:
    PDF
    Download
    Authors
    McNamara, Mairéad G
    Le, L
    Horgan, A
    Aspinall, A
    Burak, K
    Dhani, N
    Chen, E
    Sinaei, M
    Lo, G
    Kim, T
    Rogalla, P
    Bathe, O
    Knox, J
    Show allShow less
    Affiliation
    Department of Medical Oncology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; The Christie NHS Foundation Trust
    Issue Date
    2015-01-06
    
    Metadata
    Show full item record
    Abstract
    Second-line treatment options in advanced hepatocellular carcinoma (HCC) are limited. Axitinib, a selective potent tyrosine kinase inhibitor (TKI) of vascular endothelial growth factor VEGF) receptors 1, 2, and 3, merits exploration in HCC.
    Citation
    A phase II trial of second-line axitinib following prior antiangiogenic therapy in advanced hepatocellular carcinoma. 2015: Cancer
    Journal
    Cancer
    URI
    http://hdl.handle.net/10541/338773
    DOI
    10.1002/cncr.29227
    PubMed ID
    25565269
    Type
    Article
    Language
    en
    ISSN
    1097-0142
    ae974a485f413a2113503eed53cd6c53
    10.1002/cncr.29227
    Scopus Count
    Collections
    All Christie Publications

    entitlement

    Related articles

    • Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study.
    • Authors: Schiller JH, Larson T, Ou SH, Limentani S, Sandler A, Vokes E, Kim S, Liau K, Bycott P, Olszanski AJ, von Pawel J
    • Issue date: 2009 Aug 10
    • Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.
    • Authors: Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, Hutson TE, Michaelson MD, Gorbunova VA, Gore ME, Rusakov IG, Negrier S, Ou YC, Castellano D, Lim HY, Uemura H, Tarazi J, Cella D, Chen C, Rosbrook B, Kim S, Motzer RJ
    • Issue date: 2011 Dec 3
    • Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study.
    • Authors: Bruix J, Tak WY, Gasbarrini A, Santoro A, Colombo M, Lim HY, Mazzaferro V, Wiest R, Reig M, Wagner A, Bolondi L
    • Issue date: 2013 Nov
    • Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial.
    • Authors: Motzer RJ, Escudier B, Tomczak P, Hutson TE, Michaelson MD, Negrier S, Oudard S, Gore ME, Tarazi J, Hariharan S, Chen C, Rosbrook B, Kim S, Rini BI
    • Issue date: 2013 May
    • Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: a phase II study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma.
    • Authors: Tomita Y, Uemura H, Fujimoto H, Kanayama HO, Shinohara N, Nakazawa H, Imai K, Umeyama Y, Ozono S, Naito S, Akaza H, Japan Axitinib Phase II Study Group
    • Issue date: 2011 Nov
    DSpace software (copyright © 2002 - 2025)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.